Premium
Glycemic Control in Adult Surgical Patients Receiving Regular Insulin Added to Parenteral Nutrition vs Insulin Glargine: A Retrospective Chart Review
Author(s) -
Truong Stephanie,
Park Annie,
Kamalay Salem,
Hung Nancy,
Meyer Jesse G.,
Nguyen Nicole,
Momenzadeh Amanda
Publication year - 2019
Publication title -
nutrition in clinical practice
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.725
H-Index - 71
eISSN - 1941-2452
pISSN - 0884-5336
DOI - 10.1002/ncp.10252
Subject(s) - medicine , glycemic , insulin glargine , insulin , retrospective cohort study , diabetes mellitus , hypoglycemia , parenteral nutrition , endocrinology
Background Hyperglycemia is a frequent complication in patients receiving parenteral nutrition (PN) and has been associated with an increased risk of mortality. Treatment of hyperglycemia requires insulin therapy; however, the optimal dose and route have not been established. This study aimed to compare regular insulin added to PN (RI‐in‐PN) with subcutaneous insulin glargine for the management of hyperglycemia in patients receiving PN. Methods This retrospective study was conducted at a tertiary medical center and reviewed 113 adult, non–critically ill surgical patient admissions receiving PN over a 5‐year period. The primary outcome was achievement of glycemic control. Secondary outcomes were time to glycemic control, hypoglycemic events, hospital length of stay, and 1‐year mortality. Results The RI‐in‐PN group had a significantly higher percentage of patient admissions who achieved glycemic control compared with the insulin glargine group (71.8% vs 48.6%, P = 0.017). There was no difference in time to glycemic control, hypoglycemic events, hospital length of stay, or 1‐year mortality between groups. Among patients with diabetes mellitus (DM), however, the insulin glargine group had a significantly higher percentage of admissions with at least 1 hypoglycemic event (45.5% vs 20%, P = 0.035). Conclusions RI‐in‐PN is recommended over insulin glargine because of the higher likelihood of achieving glycemic control and, in patients with DM, lower risk of hypoglycemic events. Large, randomized controlled trials are needed to further guide prescribing practice.